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ABSTRACT
Myelodysplastic syndromes (MDS) are heterogeneous
clonal diseases characterized by cytopenias resulting
from ineffective hemopoiesis. Anemia affects the vast
majority of patients with MDS and contributes sub-
stantially to their symptoms. For more than 20 years,
recombinant human erythropoietin has been avail-
able for clinical use, and it has been employed in an
attempt to relieve MDS-related anemia. Erythropoi-
etin-alpha, erythropoietin-beta, and more recently
darbepoetin have been found to increase hemoglobin
levels and abolish transfusion dependence in 19%–
68% of MDS cases. This wide range in clinical re-
sponse depends on several biological and clinical
variables that allow the selection of patients with the
highest probability of successful treatment. These
agents are a mainstay in MDS therapy, but many is-
sues are still open in terms of the initiation of therapy,
the optimal dosage of erythropoietic stimulating
agents (ESAs), the most efficient type of ESA, and the
duration and outcome of such treatments. In this re-
view, the mechanisms of response and predictive fac-
tors as well as an analysis of the clinical activity of
ESAs in MDS therapy are presented. The Oncologist
2011;16(suppl 3):35–42
INTRODUCTION
Myelodysplastic syndromes (MDS) are a group of hemato-
logical neoplastic diseases with a heterogeneous clinical
presentation and, most probably, heterogeneous pathophys-
iology. Their common shared clinical feature is the pres-
ence of severe peripheral blood cytopenias. In more than
two thirds of MDS cases, anemia is present at diagnosis.
Improving erythropoiesis, and thus eliminating fatigue and
symptoms, is the main therapeutic target for the majority of
MDS patients, because 50% of patients present with ane-
mia with an Hb level 10 g/dL. Some 85% of patients de-
velop more serious anemia as MDS progresses and 80%
require red blood cell (RBC) transfusion. In a mainly ge-
riatric population of patients, anemia leads to co-morbid-
ities that include cardiac complications, increased
fatigue, diminished quality of life (QoL), and the need
for chronic RBC transfusion. Well-known problems as-
sociated with RBC transfusions are iron overload, fluc-
tuating hemoglobin levels, and persistently low
hemoglobin levels (usually 10 g/dL), in addition to the
Correspondence: Valeria Santini, M.D., Functional Unit of Haematology, AOU Careggi, University of Florence, Largo Brambilla 3,
Firenze, Italy. Telephone: 390557947296; Fax: 390557947343; e-mail: santini@unifi.it Received March 1, 2011; accepted for publi-
cation May 9, 2011. ©AlphaMed Press 1083-7159/2011/$30.00/0 doi: 10.1634/theoncologist.2011-S3-35
TheOncologist®
The Oncologist 2011;16(suppl 3):35–42 www.TheOncologist.com
intrinsic risks related to intolerance reactions, alloimmu-
nization, and infections.
Diagnostic and prognostic evaluations of MDS patients
are based on the French–American–British classification
[1], the derived International Prognostic Score System
(IPSS) [2], the World Health Organization (WHO) classi-
fication [3], or the derived WHO classification-based prog-
nostic scoring system, WPSS [4]. These prognostic systems
are strongly dependent on the morphological detection of
immature cells and on the presence of cytogenetic abnor-
malities. The IPSS (which will be revised during this cur-
rent year) divides MDS patients into a low-risk group (low
and INT-1), in which apoptotic events in the marrow are
prevalent and there is a defective response to cytokines (in-
cluding erythropoietin [EPO]), and a high-risk group (inter-
mediate-2 [INT-2] and high), in which a block in the
maturation of marrow progenitors is the principal alteration
(Figure 1). In the WPSS scoring system, transfusion depen-
dence has been characterized as an important negative
prognostic variable.
Despite all the above issues, the availability of these
agents in clinics for more than 20 years, and the recommen-
dations of several guidelines and consensus documents,
ESAs are not approved by the Food and Drug Administra-
tion (FDA) or by the European Medicines Agency (EMA)
for the treatment of anemia of MDS. The evidence for
erythropoietic stimulating agent (ESA) activity and safety
in MDS patients as well as pharmaco-economical argu-
ments are examined in this review.
BIOLOGICAL STUDIES
Although the clinical use of ESAs in MDS patients is based
on empiric observations of efficacy, some interesting stud-
ies have provided biological insights into the mechanisms
of impaired response to endogenous EPO in MDS patients
and the effects of pharmacological doses of ESAs.
It is a matter of debate whether the clinical response ob-
served in 50% of MDS cases is a result of proliferation
and maturation of the dysplastic clone or stimulation of re-
sidual normal erythropoiesis by ESAs. Over the years, ev-
idence has been provided to support both views. A few
biological studies have been reported recently.
It has been known for more than two decades that bone
marrow cells from MDS patients show an altered response
to EPO in terms of in vitro colony formation. In particular,
burst forming units erythroid (BFU-E) and colony-forming
units erythroid (CFU-E) were found to be defective in cul-
tures of unsorted and sorted CD34-positive bone marrow
MDS cells, both after exposure to EPO and after exposure
to EPO combined with interleukin-3 (IL-3), thrombopoi-
etin, and other factors usually synergistic with EPO in terms
of proliferative stimulus [5–7]. Only the addition of stem
cell factor was found to be active to some extent [8]. Other
functional parameters, such as EPO-dependent DNA syn-
thesis and induction of GATA-1 binding activity, were also
profoundly altered [9]. On the other hand, MDS progenitors
showed lower expansion of multipotent progenitors (CFU-
GEMM) in semisolid culture systems, indicating a general
disturbance of regulator cytokine production or response as
the cause of such defects [10].
EPO-specific receptors have been demonstrated on
MDS cells, and the percentage of bone marrow cells ex-
pressing the EPO receptor (EPO-R) from patients with
MDS was comparable with that of normal marrow. No
apparent correlation was evident between the number of
MDS cells coexpressing the EPO-R and CD34 or CD71-
positive cells and impaired erythroid response, and MDS
marrow cells expressed the full length EPO-R [9, 11]. It
was then postulated that intracellular structural defects of
EPO-R, although not frequently analyzed and demonstrated
[12], could cause defective receptor signaling following ligand
binding [11]. In fact, STAT5-defective activation after EPO
stimulation was observed in parallel with conserved STAT5
phosphorylation upon stimulation with IL-3, and this was at-
tributed to a disturbance in an early stage of the EPO signal
transduction pathway [9] (Figure 2).
On the other hand, the typical clinical characteristics of
MDS—peripheral cytopenias with hyperproliferative mar-
row and ineffective hemopoiesis—appear to be related to
the presence of excessive premature apoptosis of hemato-
poietic precursors. Several groups have demonstrated a
higher number of apoptotic cells in the bone marrow of
MDS patients [13–15]. Tumor necrosis factor alpha and in-
terferon gamma are thought to participate in this apoptotic
process [16]. Therefore, the typical dyserythropoiesis in
Figure 1. Myelodysplastic syndromes (MDS) patients are di-
vided into a lower-risk group, in which apoptotic events in the
marrow are prevalent and there is a defective response to cy-
tokines (including erythropoietin), and a higher-risk group, in
which a block in the maturation of marrow progenitors is the
principal alteration.
36 Use of ESAs in Myelodysplastic Syndromes
MDS has been directly linked to greater expression of the
transmembrane mediator of apoptotic cell death Fas/CD95
in the glycophorin A subpopulation [17] (Figure 2).
From this cumulative evidence, we may conclude that
the ineffective erythropoiesis in MDS is caused by a defect
in EPO-induced antiapoptotic pathways and by the stimu-
lation of proapoptotic signals. Both obstacles to prolifera-
tion and maturation and to excessive apoptosis of erythroid
precursors in MDS could be overcome by the use of phar-
macological doses of EPO if we hypothesize that the dys-
plastic clones are the ones that are induced to differentiate
and finally to recover.
The clinical observation that recently diagnosed MDS
patients, who presumably have more residual polyclonal
hematopoiesis, respond better to EPO treatment could ar-
gue against all the above-mentioned evidence of MDS pro-
genitor sensitivity to ESAs. In this sense, the finding that
EPO therapy reduces the number of cytogenetically abnor-
mal clones in responding MDS patients, but not in unre-
sponsive ones, is suggestive of a response to EPO
attributable to karyotypically normal erythroid precursors,
representing residual normal polyclonal hematopoiesis
[18].
PREDICTION OF RESPONSE
A rather large number of studies have addressed the possi-
bility of identifying biological and clinical pretreatment cri-
teria to predict response to EPO. The idea is to identify
MDS patients who would most probably benefit from treat-
ment, avoiding failures and/or inappropriately long and
costly therapies.
Biological Parameters
Recently, flow cytometry analysis of MDS marrow has be-
come more common. Although flow cytometry is still a
method that requires specialist expertise and is not yet gen-
erally available in the routine diagnostic armamentarium,
there are clear guidelines expressed by the European Leu-
kemiaNet defining minimal combinations of antibodies to
analyze aberrant immunophenotypes in individual cases of
MDS. This enables the detection of altered numbers of
CD34-positive precursors, aberrant expression of markers
on myeloblasts, maturing myeloid cells, monocytes, or ery-
throid precursors, and the expression of lineage infidelity
markers [19]. Such analyses of the pattern of expressed an-
tigens revealed aberrant phenotypes of myeloblasts that
were strongly associated with nonresponders among MDS
patients with the greatest EPO response probability accord-
ing to the predictive model of Hellström-Lindberg et al.
(see below). This new predictive model may define three
subgroups among IPSS low-risk MDS patients who will re-
spond clinically to EPO treatment with a probability of
94%, 17%, and 11%, respectively [20].
Interestingly, in a small number of IPSS low-risk MDS
patients (who constitute the ideal patient population for
ESAs), the gene expression profile was investigated in
sorted bone marrow glycophorin-positive erythroid cells
and was found to correlate with their clinical response to
Figure 2. STAT5-defective activation after erythropoietin (EPO) stimulation was observed in parallel with conserved STAT5




EPO [21]. MDS case subjects who were nonresponsive to
EPO showed repressed expression of genes responsible for
proliferation/differentiation and DNA repair/stability,
which were almost normally expressed in responders, in
whom genes related to signal transduction, and in particular
to the mitogen-activated protein kinase signaling pathway,
seemed inhibited. This kind of analysis is now ongoing in a
larger number of MDS cases, and it constitutes a challeng-
ing approach to the molecular mechanisms underlying ESA
responsiveness.
In a much larger cohort of low/INT-1 MDS patients at
diagnosis (127), MDS cases who were nonresponders to
ESAs had a significantly lower number of BFU-E and
CFU-E than responders. Moreover, EPO-dependent
ERK1/2 activation was significantly lower in CD45neg/
CD71pos/GPAneg bone marrow cells from ESA nonre-
sponders than ESA responders, and it could predict clinical
response to ESAs [22].
Our group also found a correlation between EPO signal
transduction alteration observed in vitro with a flow cytom-
etry method and a lack of response to ESA treatment. In our
study, CD71-positive marrow cells obtained from low/
INT-1 MDS patients not responding to ESAs demonstrated
defective or absent EPO-driven STAT5 phosphorylation
[23].
Clinical Parameters
EPO has been used in MDS since the late 1980s. During
that time, several authors have focused on establishing re-
sponse criteria to this agent, and analyses and meta-analy-
ses of clinical trials with huge numbers of treated patients
have led to some sound conclusions.
Very early observations indicated that MDS patients
without a need for transfusion, with a serum EPO level
200 U/L, and a diagnosis other than refractory cytopenia
with multilineage dysplasia with ringed sideroblasts
(RARS) had a 68% response rate to EPO. On the other
hand, RARS patients with or without a need for transfusion
but with a serum EPO level 200 U/L had a response rate
as low as 0% [24]. Overall, the response to EPO ranged
from a maximum of 68% to a minimum of 19% in unse-
lected cases, excluding RARS cases. A meta-analysis of
published studies (1990 –2005) on ESA treatment [25]
showed that low transfusion dependence, a morphological
diagnosis of RA/RARS, the use of a fixed-dose versus
weight-based EPO regimen, a shorter time from diagnosis
to starting treatment, and a lower serum EPO level were the
parameters predictive of response to ESA therapy.
An EPO level 200 U/L, transfusion dependence, an
IPSS score of high and, in particular, 10% blasts in the
marrow, and a longer time elapsed from diagnosis were
demonstrated to be negative predictive factors for response
to EPO, EPO plus granulocyte colony-stimulating factor
(G-CSF), and darbepoetin [26].
Although validated for therapy with EPO plus G-CSF
[27], a practical scoring system was developed to select
MDS patients with a high probability of response to treat-
ment. Transfusion need and serum EPO level were still the
variables considered.
The probability of response was in the range of 74% for
a score of 0 to 23% for a score of 1, and 7% for a score of 2,
where a score of 0 corresponds to a transfusion need 2
U/mo and a serum EPO level 500 U/L and higher levels
for both transfusion need and EPO level are required for
scores of 1 and 2. In a recently reported study, a poorer re-
sponse to ESAs was observed in MDS patients with the fol-
lowing characteristics: transfusion dependence, EPO level
200 U/L, a morphological diagnosis of refractory anemia
with excess blasts (RAEB2) and refractory cytopenia with
multilineage dysplasia with ringed sideroblasts (RCMD-
RS), and abnormal karyotype [28] (Table 1).
Although not much evidence is available and published
in this regard, patients with a 5q chromosomal abnormality
seem to respond to ESAs (both EPO and darbepoetin with
or without G-CSF), with a significantly lower response rate
and significantly shorter duration of response to both EPO
and darbepoetin (with or without G-CSF) than MDS pa-
tients without del 5q [29]. Further evaluation of clinical re-
sponse to ESA therapy in del (5q) patients is required. In
this subgroup of patients, in cases of transfusion depen-
dence, treatment with lenalidomide has been approved by
the FDA, but not by the EMA. All parameters of response to
ESAs for MDS patients are summarized in Table 1.
CLINICAL EFFICACY
Soon after human recombinant EPO became available in
clinics for renal failure patients, it was used for the treat-
ment of anemia in MDS patients. At present, there are
published reports of treatment with ESAs for 2,500
MDS patients. Quite recently, three meta-analyses ad-
dressed the efficacy of ESAs (EPO and darbepoetin) in
MDS patients (3,025 and 2,530, respectively) [37]. Since
2000, International Working Group (IWG) criteria for
the evaluation of response have been proposed in two
subsequent versions (2000 and 2006), and since then, as
unified and codified parameters of response are applied,
evaluation and comparison of results from different stud-
ies are possible [31, 32].
A meta-analysis by Ross and colleagues pooled the data
of 1,936 patients from 59 trials and included 5 studies (354
patients) randomizing Low-INT-1 IPSS risk MDS patients
to either EPO with or without G-CSF or granulocyte mac-
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rophage colony-stimulating factor (GM-CSF) or supportive
care, wherein a relevant erythroid response was demon-
strated in 27% of the patients. There were then reports of 51
EPO clinical studies and 3 darbepoetin single-arm studies.
Response rates were higher (32%– 48%) in uncontrolled
studies and even better after longer treatments [20 wk(s)]
and with iron supplementation.
A second meta-analysis by Moyo et al. pooled data from
30 rigorously selected studies (of 79 published) treating
MDS patients with rHuEpo-alpha (22 studies, 925 patients;
13 studies not employing IWG response criteria) or darbe-
poetin (8 studies, 389 patients), in monotherapy, but includ-
ing recent clinical trials with higher ESA dosing. The
pooled erythroid response rate was 43.9%. For the studies
that did not apply the IWG criteria, the response rate was as
low as 31.6%, whereas it was 57.6% for IWG-based stud-
ies. A comparison between erythropoietin darbepoetin was
thus performed only for the IWG-based studies (9 EPO-
alpha and 8 darbepoetin), and no statistically significant
difference was noted when the erythroid response rate was
compared between the two agents at corresponding dosing
regimens. On the other hand, higher dosing regimens of
both EPO-alpha (60,000 – 80,000 U/wk) and darbepoetin
(300 g/wk) yielded greater erythroid responses. Regard-
ing higher dosages of ESAs, several trials reported rates of
erythroid response of 50%–71% in lower-risk MDS pa-
tients treated with high doses of rHuEpo (60,000–80,000
U/wk) [32, 33] (3,334 and 3,435) or darbepoetin (300 mcg
once weekly or 500 g every 2–3 weeks) (3,536). Quite re-
cently, it became evident that earlier inception of ESA ther-
apy may delay the need for transfusion and substantially
increase, for a longer period, the hemoglobin level (63.1%
response rate) [37]. On the other hand, it has been well
known for some time that a longer duration of ESA treat-
ment may recruit later responders, with a significant differ-
ence in the rate of response at 26 weeks versus 12 weeks [38].
At least a dozen studies have been published investigat-
ing the efficacy of the combination of EPO (or darbepoetin)
plus G-CSF (or GM-CSF) in MDS patients, based on pos-
sible synergistic activity previously demonstrated, and
claiming a higher rate of response to EPO as a single drug,
mostly in transfusion-dependent and RARS patients. A
meta-analysis performed by Mundle et al. specifically as-
sessed the erythroid response to EPO-alpha monotherapy
versus that obtained with EPO-alpha plus G-CSF or GM-
CSF. Fifteen studies fulfilled the criteria for the meta-
analysis, enrolling 741 patients. The rates of erythroid
response were comparable (50%) with the two treatment
modalities. Higher doses of EPO-alpha induced a higher
number of responses, superior to what was observed with
standard dose EPO plus G-/GM-CSF [39].
The majority of clinical studies of ESAs in MDS pa-
tients use EPO-alpha. Few data have been published for
EPO-beta, and these are mainly in combination with G-CSF
or all-trans retinoic acid (ATRA). Recently, increasing
numbers of investigators have tested the activity of darbe-
poetin, whose peculiar pharmacokinetics could produce
different response rates (3,840).
During ESA therapy, a conspicuous number of MDS
patients may lose responsiveness. This may result from sev-
eral factors, including depletion of iron, which occurs fre-
quently. Normal iron levels should be restored by
supplementation, even in cases of normal ferritin. Progres-
sion of MDS to IPSS higher risk/acute myeloid leukemia
may demonstrate loss of sensitivity to ESAs but this could
also indicate concomitant severe infections (production of
cytokine suppressing erythropoiesis) or the development
of autoimmune antierythrocyte antibodies.
No data are currently available regarding the efficacy of
long-acting ESAs or EPO biosimilars in MDS patients.
Diverse therapeutic strategies and combinations of differ-
entiation agents have been proposed to optimize the activity of
ESAs in MDS patients. EPO has been combined with ATRA
[41, 42], and good results were obtained for MDS patients who
had failed previous ESA therapy (36% response rate accord-
ing to the IWG 2006 criteria) or who had transfusion depen-
dence (response rate, 39%). No advantage was seen for
patients with an endogenous EPO level 500 U/L or with ad-
ditional cytopenias. Other combinations, for example, EPO
plus thalidomide and EPO plus lenalidomide, have been stud-
ied in a limited number of cases, the first with no advantage in
anemia relief and the latter with a significantly higher inci-
dence of thromboembolic events.
Some years ago, our group reported a sustained and
rapid response to azacitidine combined with high-dose
EPO-alpha in 10 IPSS INT-1 risk MDS patients [43]. Al-
though safe as a combination therapy, it is not clear whether
Table 1. Predictive variables for ESA response in MDS
Biological
Endogenous erythropoietin levels 500 U/L
Marrow blast 10%
IPSS low-INT-1




Short duration of disease
Abbreviations: ESA, erythropoietic stimulating agents;
INT-1, intermediate-1; IPSS, International Prognostic
Score System; MDS, myelodysplastic syndromes.
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the improved erythropoiesis observed was a result of an ef-
fect of azacitidine or restoration of sensitivity to EPO-
alpha. No further systematic studies of such a combination
have been published.
SAFETY
The use of ESAs in cancer, with or without chemotherapy,
contributes to a lower need for transfusions and a higher he-
matocrit level, but these beneficial effects are not accompa-
nied by longer survival, nor are they devoid of side effects,
frequently caused by the presence of functional active re-
ceptors on neoplastic cells or on cells other than erythroid
(i.e., endothelial) cells. In certain cases, ESAs have been
demonstrated to be detrimental, because some reports sug-
gested a shorter survival duration in patients with solid can-
cers treated with ESAs [44]. These observations, some
years ago, prompted a critical reevaluation of ESA use in
oncology practice, mainly in the U.S. Moreover, this evi-
dence led the FDA to instruct the producers of ESAs to add
a “black box” warning to the package insert of these agents.
Consequently, the banning of their indiscriminate use in
cancer in general, including MDS, was supported by a
memo from the Centers for Medicare and Medicaid Ser-
vices.
The evidence in MDS is, in fact, quite different. Regard-
ing thromboembolic events during ESA treatment, there are
few published reports involving MDS patients [45– 47],
whereas in several meta-analyses of clinical trials with
EPO, including several thousands of patients, no episodes
of hypertension, seizures, or cardiovascular events directly
resulting from the growth factor were reported [25, 39, 48,
49]. In contrast, several studies indicated longer survival
times in MDS patients responding to therapy with ESAs
[26] (50 and 51).
Still, a proportion of patients, generally geriatric, with
suspected MDS-related anemia are treated with ESAs on an
empirical basis, without any proper diagnosis. This practice
should be stopped, not only because of cost-effectiveness
issues but also because we need more prospective, long-
term studies of EPO versus placebo to definitively deter-
mine the safety of such therapy in MDS patients (52).
Overall, the use of ESAs in MDS therapy has remained
safe, provided published guidelines are followed.
GUIDELINES
The first systematic guidelines for the treatment of MDS
patients were produced by the Italian Society of Hematol-
ogy in 2002 (53). A recent update of these guidelines (54)
devoted particular attention to recommendations regarding
the correct use of ESAs, according to the evidence pro-
duced in the last several years. In particular, a grade B rec-
ommendation indicates that patients with low-INT-1 IPSS
risk MDS, with a hemoglobin level 10 g/dL and a serum
erythropoietin level 500 IU/mL, should be considered for
ESAs, that is, EPO-alpha, EPO-beta, or darbepoetin. The
updated recommendations also consider follow-up of treat-
ment, as reported below: “Fixed, rather than weight-ad-
justed, weekly subcutaneous doses of 60 – 80,000 U
erythropoietin (once-a-week or subdivided in two doses)
(grade A) or 300 mcg darbepoetin (once-a-week) should be
used (grade B) for at least 12 weeks, possibly more than 20
(grade B). During ESA treatment, iron supplementation
should be considered for patients with a transferrin satura-
tion  20% (grade D). If the patient responds to ESA treat-
ment, an attempt should be made to reduce the dose (or the
frequency of administration) to the lowest effective sched-
ule able to maintain the hemoglobin level between 10 and
12 g/dL (grade D). The combination of ESAs and G-CSF
should be considered only for patients who are not heavily
(2U per month) red-cell transfusion dependent with se-
rum erythropoietin levels 500 mIU/mL and not respond-
ing to ESAs alone (grade C)” [54].
The last update of the 2011 National Comprehensive
Cancer Network guidelines [55] acknowledges the fact that
anemia is a major issue in MDS patients to be addressed
even more carefully than in the past. An entire subsection of
the guidelines is, in fact, dedicated to the evaluation of
MDS-related anemia, therapy, and follow-up. Quite simi-
larly to what was stated in the updated Italian Guidelines, in
cases of symptomatic anemia, in IPSS low or INT-1 MDS
patients, the driving parameter to choose treatment is indi-
cated by the level of endogenous EPO. If EPO  500U/L,
the treatment of choice is EPO-alpha, 40,000–60,000 U,
1–3 times weekly subcutaneously (s.c.), or darbepoetin,
150–300 g weekly s.c. In cases of the presence of ringed
sideroblasts or an absence of response, the addition of G-
CSF, 1–2 g/kg 1–3 times per week should be considered,
as well as therapy with immunosuppressive or hypomethy-
lating agents when endogenous EPO levels are 500 U/L.
Quite importantly, in 2007, the American Society of He-
matology and the American Society of Clinical Oncology
produced guidelines [56] for the correct use of ESAs in can-
cer patients. In this work, it was stressed that the only avail-
able evidence for the successful use of ESAs in anemia
without chemotherapy was related to MDS. Only for MDS,
in fact, had there been a randomized study [57] versus pla-
cebo (level of evidence II), although the lack of randomized
trials evaluating EPO dosing was noted.
HEALTH ECONOMY ASSESSMENT
Although ESAs have been demonstrated to be effective at
increasing hemoglobin levels and decreasing transfusion
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needs and cardiac comorbidities, with a subsequent im-
provement in QoL, the number of MDS patients with symp-
tomatic anemia who require treatment is quite large and the
economic burden of this type of therapy has to be carefully
considered. The annual cost of therapy with EPO-alpha has
been compared with that of darbepoetin and found to be less
($26,076 –$52,176 versus $41,904 –$87,300 annually),
with similar efficacy. Costs are equivalent whether first-
line, second-line, or third-line treatment is analyzed and are
in the same range of annual costs of azacitidine and decit-
abine, with lenalidomide treatment being more expensive
[58]. Although the choice of treatment by physicians should
not be biased by the cost of such treatment, the problem of
sustainability arises in a disease like MDS, which mainly
affects the geriatric population, which is steadily increasing
in number in western societies. The optimization of treat-
ment involves the good use of ESAs through strict selection
of MDS patients with a high probability of response, based
on the available and validated parameters. On the other
hand, more studies are needed to clarify the economic bur-
den of so-called “supportive care measures” [59] versus ac-
tive therapy, balancing efficacy, outcome (survival),
comorbidities, and, last but not least, the QoL of affected
patients [60].
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